{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:05:44Z","timestamp":1792130744923,"version":"4.4.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tibtech.2026.07.027","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:26:21Z","timestamp":1786739181000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In situ programming of unconventional T cells"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tibtech.2026.07.027_bb0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0015","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","article-title":"Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks","volume":"22","author":"Diorio","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0035","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med (New York, N. Y.)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0040","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.3390\/cancers16244266","article-title":"Targeting of non-classical human leukocyte antigens as novel therapeutic strategies in cancer","volume":"16","author":"Benitez Fuentes","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0045","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1186\/s12967-023-04575-9","article-title":"Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies","volume":"21","author":"Li","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0060","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.3390\/cells10123497","article-title":"Development of stem cell-derived immune cells for off-the-shelf cancer immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ccell.2024.11.010","article-title":"Breaking the mold: unconventional T cells in cancer therapy","volume":"43","author":"Li","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101342","article-title":"iNKT: a new avenue for CAR-based cancer immunotherapy","volume":"17","author":"Liu","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41577-019-0191-y","article-title":"Mucosal-associated invariant T cells and disease","volume":"19","author":"Toubal","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0080","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/s41577-020-0345-y","article-title":"Thymic development of unconventional T cells: how NKT cells, MAIT cells and \u03b3\u03b4 T cells emerge","volume":"20","author":"Pellicci","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(09)01201-2","article-title":"Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity","volume":"102","author":"Cohen","year":"2009","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-018-0034-2","article-title":"Tissue-specific functions of invariant natural killer T cells","volume":"18","author":"Crosby","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0095","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41577-023-00934-1","article-title":"MR1 antigen presentation to MAIT cells and other MR1-restricted T cells","volume":"24","author":"McWilliam","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0100","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science (1979)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.immuni.2020.02.014","article-title":"Butyrophilin-2A1 directly binds germline-encoded regions of the V\u03b39V\u03b42 TCR and is essential for phosphoantigen sensing","volume":"52","author":"Karunakaran","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0110","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41586-023-06525-3","article-title":"Phosphoantigens glue butyrophilin 3A1 and 2A1 to activate V\u03b39V\u03b42 T cells","volume":"621","author":"Yuan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0115","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s41590-024-01892-z","article-title":"V\u03b39V\u03b42 T cells recognize butyrophilin 2A1 and 3A1 heteromers","volume":"25","author":"Fulford","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0120","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0125","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","article-title":"Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Mavers","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0130","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.3390\/ijms24044084","article-title":"Graft-versus-host disease modulation by innate T cells","volume":"24","author":"Fang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0135","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0140","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.3390\/cancers13205174","article-title":"The current landscape of NKT cell immunotherapy and the hills ahead","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T cells for cancer immunotherapy","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0155","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.celrep.2016.04.081","article-title":"RhoB mediates phosphoantigen recognition by V\u03b39V\u03b42 T cell receptor","volume":"15","author":"Sebestyen","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108457","article-title":"A phase I study of loco-regional immunotherapy by transbronchial injection of \u03b1-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer","volume":"215","author":"Ishibashi","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0175","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.8.7.875","article-title":"Aminobisphosphonate-activated \u03b3\u03b4 T cells in immunotherapy of cancer: doubts no more","volume":"8","author":"Caccamo","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers12020413","article-title":"MAIT cells come to the rescue in cancer immunotherapy?","volume":"12","author":"Lukasik","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0185","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1172\/JCI24762","article-title":"Glycolipid antigen induces long-term natural killer T cell anergy in mice","volume":"115","author":"Parekh","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0195","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1172\/JCI26297","article-title":"Activation or anergy: NKT cells are stunned by \u03b1-galactosylceramide","volume":"115","author":"Sullivan","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0200","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.1038\/s41598-018-26470-w","article-title":"Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice","volume":"8","author":"Uchida","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0205","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ni827","article-title":"Prolonged IFN-\u03b3\u2013producing NKT response induced with \u03b1-galactosylceramide-loaded DCs","volume":"3","author":"Fujii","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0210","article-title":"Feeder-free advances in T cell development and therapy","volume":"2","author":"Zhu","year":"2025","journal-title":"Cell Biomater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0215","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1016\/j.scib.2025.04.041","article-title":"Biomaterials mimicking immunological synapses for enhanced T cell activation in CAR-T therapy","volume":"70","author":"Li","year":"2025","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0220","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.celbio.2026.100380","article-title":"Engineering biomaterials for next-generation cancer immunotherapy: from cell manufacturing to in vivo modulation","volume":"2","author":"Liu","year":"2026","journal-title":"Cell Biomater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01629-3","article-title":"Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy","author":"Li","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0235","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature13160","article-title":"T-cell activation by transitory neo-antigens derived from distinct microbial pathways","volume":"509","author":"Corbett","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adq1975","article-title":"An electroadhesive hydrogel interface prolongs porcine gastrointestinal mucosal theranostics","volume":"17","author":"Ying","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2022.11.015","article-title":"Oral vaccination using microdevices to deliver \u03b1-GalCer adjuvanted vaccine afford a mucosal immune response","volume":"353","author":"Carlsen","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0255","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41587-022-01510-z","article-title":"A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy","volume":"41","author":"Quijano-Rubio","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0260","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41467-023-37646-y","article-title":"Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models","volume":"14","author":"Yang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0265","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy\u2013safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0270","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-026-02602-x","article-title":"Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0275","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0280","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0285","first-page":"1655","article-title":"Broadening the message: a nanovaccine co-loaded with messenger RNA and \u03b1-GalCer induces antitumor immunity through conventional and natural killer T cells","volume":"13","author":"Verbeke","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0290","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.2147\/IJN.S479741","article-title":"Nasal mRNA nanovaccine with key activators of dendritic and MAIT cells for effective against lung tumor metastasis in mice model","volume":"19","author":"Li","year":"2024","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0295","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jconrel.2022.09.038","article-title":"Mannose in vaccine delivery","volume":"351","author":"Nahar","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/cjoc.202400876","article-title":"Bioorthogonal cleavage chemistry: harnessing the bond-break reactions for biomolecule manipulations in living systems","volume":"43","author":"Zhu","year":"2025","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0305","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0310","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41578-023-00617-2","article-title":"Responsive biomaterials: optimizing control of cancer immunotherapy","volume":"9","author":"Xue","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0315","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0320","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0325","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymthe.2018.10.006","article-title":"In vivo PET tracking of 89Zr-labeled V\u03b39V\u03b42 T cells to mouse xenograft breast tumors activated with liposomal alendronate","volume":"27","author":"Man","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0330","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0335","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/cmdc.202000198","article-title":"Structure-activity relationships of butyrophilin 3 ligands","volume":"15","author":"Wiemer","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0340","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","article-title":"Vaccine adjuvants: mechanisms and platforms","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0350","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2026.119385","article-title":"Inflammatory and immune-mediated toxicity of lipid nanoparticles","volume":"199","author":"Kim","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0360","article-title":"Next-generation long-acting injectables: technological innovations and patient-centric design in complex drug delivery systems","volume":"121","author":"Jain","year":"2026","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0365","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0370","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities","volume":"17","author":"Karlsson","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0375","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-023-39938-9","article-title":"mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0380","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0385","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0390","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-252","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0395","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aee6253","article-title":"Cancer-fighting cells made in body help patients","volume":"390","author":"Leslie","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0400","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","article-title":"In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study","volume":"32","author":"An","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0405","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0410","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0415","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/s41551-024-01272-w","article-title":"Viscoelastic synthetic antigen-presenting cells for augmenting the potency of cancer therapies","volume":"8","author":"Liu","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0420","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1038\/s41596-025-01265-2","article-title":"Manufacturing synthetic viscoelastic antigen-presenting cells for immunotherapy","volume":"21","author":"Liu","year":"2025","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0425","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/cancers12010104","article-title":"Nanoformulated zoledronic acid boosts the V\u03b42 T cell immunotherapeutic potential in colorectal cancer","volume":"12","author":"Di Mascolo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0430","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/00914037.2022.2082425","article-title":"Bisphosphonate-loaded PLGA microspheres for bone regeneration in dental surgery: formulation, characterization, stability, and comprehensive release kinetic studies","volume":"72","author":"\u00dcnal","year":"2023","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0435","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S580230","article-title":"Translational nanomedicine for osteoporosis: bridging bone signaling networks and targeted delivery systems","volume":"21","author":"Liu","year":"2026","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41590-019-0416-z","article-title":"Humanized immune system mouse models: progress, challenges and opportunities","volume":"20","author":"Allen","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0445","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0450","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41590-019-0444-8","article-title":"The biology and functional importance of MAIT cells","volume":"20","author":"Godfrey","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0455","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1642022","article-title":"Frontiers of cytokine engineering in CAR cell therapy for cancer","volume":"15","author":"Wu","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0460","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid\u2013polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114385","article-title":"Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles","volume":"388","author":"Baghel","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0470","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01656-0","article-title":"CAR-neutrophils produced in vivo to treat glioma","author":"Chang","year":"2026","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0480","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.ymthe.2023.08.018","article-title":"FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment","volume":"31","author":"Hartmann","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0485","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/s41385-022-00566-z","article-title":"A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity","volume":"15","author":"Anna","year":"2022","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0490","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.10","article-title":"Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals","volume":"1","author":"Pridans","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0495","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41586-021-03578-0","article-title":"A multilayered immune system through the lens of unconventional T cells","volume":"595","author":"Mayassi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0500","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.2147\/IJN.S112432","article-title":"Improved proliferation of antigen-specific cytolytic T lymphocytes using a multimodal nanovaccine","volume":"11","author":"Li","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0505","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1339855","article-title":"Co-delivery of the NKT agonist \u03b1-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses","volume":"6","author":"Ghinnagow","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0510","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2020.02043","article-title":"Targeted co-delivery of tumor antigen and \u03b1-galactosylceramide to CD141+ dendritic cells induces a potent tumor antigen-specific human CD8+ T cell response in human immune system mice","volume":"11","author":"Huang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0515","doi-asserted-by":"crossref","first-page":"5838","DOI":"10.1016\/j.vaccine.2015.08.083","article-title":"Synthetic TRP2 long-peptide and \u03b1-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression","volume":"33","author":"Neumann","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0520","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641703","article-title":"PLGA nanoparticles co-encapsulating NY-ESO-1 peptides and IMM60 induce robust CD8 and CD4 T cell and B cell responses","volume":"12","author":"D\u00f6len","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0525","doi-asserted-by":"crossref","first-page":"15838","DOI":"10.1021\/jacs.3c02679","article-title":"Antigen\/adjuvant-displaying enveloped viral replica as a self-adjuvanting anti-breast-cancer vaccine candidate","volume":"145","author":"Ito","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0530","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsomega.9b00489","article-title":"Codelivery of mRNA with \u03b1-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration","volume":"4","author":"Guevara","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010673","article-title":"Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy","volume":"13","author":"Van der Vreken","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0540","article-title":"\u03b1-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy","volume":"32","author":"Zhang","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0545","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/0008-5472.CAN-20-2219","article-title":"Serial stimulation of invariant natural killer T cells with covalently stabilized bispecific T-cell engagers generates antitumor immunity while avoiding anergy","volume":"81","author":"Kharkwal","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0550","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1182\/bloodadvances.2022008118","article-title":"Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA","volume":"6","author":"Casey","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0555","article-title":"An in vivo MAIT cell activation and rejuvenation system for liver cancer therapy","author":"Li","year":"2026","journal-title":"Res. Sq."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0560","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.cell.2023.07.026","article-title":"Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin","volume":"186","author":"Ruf","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0565","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.4049\/jimmunol.1402200","article-title":"Adoptive immunotherapy of epithelial ovarian cancer with V\u03b39V\u03b42 T cells, potentiated by liposomal alendronic acid","volume":"193","author":"Parente-Pereira","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0570","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia","volume":"35","author":"Ganesan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.tibtech.2026.07.027_bb0575","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-20-4576","article-title":"A bispecific single-domain antibody boosts autologous V\u03b39V\u03b42-T cell responses toward CD1d in chronic lymphocytic leukemia","volume":"27","author":"de Weerdt","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0580","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.4049\/jimmunol.2200185","article-title":"Cutting edge: bispecific \u03b3\u03b4 T cell engager containing heterodimeric BTN2A1 and BTN3A1 promotes targeted activation of V\u03b39V\u03b42+ T cells in the presence of costimulation by CD28 or NKG2D","volume":"209","author":"Lai","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0585","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-23-0189","article-title":"A bispecific \u03b3\u03b4 T-cell engager targeting EGFR activates a potent V\u03b39V\u03b42 T cell\u2013mediated immune response against EGFR-expressing tumors","volume":"11","author":"King","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0590","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/s41565-024-01781-4","article-title":"Biomimetic cell stimulation with a graphene oxide antigen-presenting platform for developing T cell-based therapies","volume":"19","author":"Zhu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103957","article-title":"Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging","volume":"6","author":"Lyu","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103810","article-title":"Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity","volume":"6","author":"Fang","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.tibtech.2026.07.027_bb0605","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926003239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779926003239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T10:52:57Z","timestamp":1786877577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779926003239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":121,"alternative-id":["S0167779926003239"],"URL":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.07.027","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In situ programming of unconventional T cells","name":"articletitle","label":"Article Title"},{"value":"Trends in Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tibtech.2026.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}